Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients
Copyright © 2019 Elsevier Ltd. All rights reserved..
microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, changes in microRNAs are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues in patients of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis and depression. Compared with other bodily fluids, CSF is the most accurate at representing the pathological processes of the brain. To understand whether microRNA expression may be dysregulated in the patients of PD, and to further discover potential diagnostic biomarkers and promising therapeutic targets for PD, we used real-time polymerase chain reaction (RT-PCR) to compare CSF microRNAs from 20 PD patients, 13 AD patients and 27 controls with other neurologic disorders such as encephalitis and Guillain-Barre syndrome. Finally, we found that the mean expression level of hsa-miR-626 was significantly reduced in the CSF of patients with PD compared with AD and controls. Our approach potentially identified a biomarker in CSF that upon further investigation, could be used for the detection, diagnosis, and monitoring of PD in combination with other PD biomarkers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia - 70(2019) vom: 30. Dez., Seite 198-201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qin, Li-Xia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 05.02.2020 Date Revised 05.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jocn.2019.08.082 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301014191 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301014191 | ||
| 003 | DE-627 | ||
| 005 | 20231225103740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jocn.2019.08.082 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1003.xml |
| 035 | |a (DE-627)NLM301014191 | ||
| 035 | |a (NLM)31492481 | ||
| 035 | |a (PII)S0967-5868(19)30090-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qin, Li-Xia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2020 | ||
| 500 | |a Date Revised 05.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a microRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, changes in microRNAs are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues in patients of central nervous system diseases, including glioma, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis and depression. Compared with other bodily fluids, CSF is the most accurate at representing the pathological processes of the brain. To understand whether microRNA expression may be dysregulated in the patients of PD, and to further discover potential diagnostic biomarkers and promising therapeutic targets for PD, we used real-time polymerase chain reaction (RT-PCR) to compare CSF microRNAs from 20 PD patients, 13 AD patients and 27 controls with other neurologic disorders such as encephalitis and Guillain-Barre syndrome. Finally, we found that the mean expression level of hsa-miR-626 was significantly reduced in the CSF of patients with PD compared with AD and controls. Our approach potentially identified a biomarker in CSF that upon further investigation, could be used for the detection, diagnosis, and monitoring of PD in combination with other PD biomarkers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Cerebrospinal fluid | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a hsa-miR-626 | |
| 650 | 4 | |a microRNAs | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a MIRN626 microRNA, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Tan, Jie-Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hai-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Jian-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Xiang-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Bei-Sha |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chun-Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia |d 1994 |g 70(2019) vom: 30. Dez., Seite 198-201 |w (DE-627)NLM093767099 |x 1532-2653 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2019 |g day:30 |g month:12 |g pages:198-201 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jocn.2019.08.082 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2019 |b 30 |c 12 |h 198-201 | ||